Affiliation:
1. V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Abstract
Hyperprolactinemia is one of the common undesirable phenomena of antipsychotic therapy, as it is associated with a number of mental and somatic complications. To date, there are several strategies for the correction of antipsychotics induced hyperprolactinemia, the most evidential basis of which has an addition to the current treatment of partial dopamine agonist — aripiprazole.Other drugs in this group, cariprazine and brexpiprazole, due to a similar mechanism of action with aripiprazole, belong to prolactin-saving drugs. However, their differences in pharmacodynamics may determine features in prolactin effects and attract attention for further study of their prolactin-saving activity.
Publisher
V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology
Reference61 articles.
1. Gorobets LN, Mazo GE. Hyperprolactinemia during application of second-generation antipsychotics:the principles of prevention, diagnosis and correction. Obozreniepsihiatriiimedicinskojpsihologiiim. V.M. Bekhtereva. 2017;1:63–70. (In Russ.).
2. Mazo GE, Kibitov AO. Modern Possibilities of Therapeutic Correction of AntipsychoticsInduced Hyperprolactinemia. SovremennayaterapiyaPsihicheskihRasstrojstv. 2020;1:29–36. (In Russ.). doi.org/10.21265/PSYPH.2020
3. Mazo GE, Gorobets LN. Complications of neuroleptic hyperprolactinaemia. Obozreniepsihiatriiimedicinskojpsihologiiim. V.M. Bekhtereva. 2018;2:104108. (In Russ.). doi.org/10.31363/2313-7053-2018-2-104-108(In Russ.).
4. Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov. Disord. 2009:15(24):129–133.
5. Arakawa R, Okumura M, Ito H, Takano A, Takahashi H, Takano Het al. Positron emission tomography measurement of dopamine D receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J. Clin. Psychiatry. 2010;71:1131-1137.